… in Cambridge, Massachusetts, USA, developing innovative RNA-editing medicines through its proprietary Axiomer™ … strategy, provide medical leadership and advance RNA-editing therapies from concept to clinical evidence. We … shape early clinical-development strategy and help advance RNA-editing therapies for patients. You will combine hands-on …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …
… of the communities we serve. Our proprietary Axiomer™ RNA editing technology platform enables the editing of … in RNA using the cells own editing machinery. Axiomer RNA editing technology harnesses ADAR (Adenosine Deaminase … currently untreatable diseases. By harnessing the power of RNA editing, we aim to create a world where genetics inform …